announces the release of a market assessment report on the " Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimers Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2031" The Global GLP-1 Market is valued at US$ 44.5 Mn in 2023, and it is expected to reach US$ 95.4 Mn by 2031, with a CAGR of 10.3% during the forecast period of 2024-2031
Drinking water immediately after dosing washes away peptide that was still in contact with the sublingual tissue
they felt more confident, lighter, more attractive, and even more emotionally open to intimacy
